0IV3.LGeron Corporation

Acerca de

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

www.geron.com

Estadísticas clave

Cap. de mercado

853.83M

BPA

-0.13

Rend. dividendo

0.00%

Beta

0.60

P/VC

3.98

ROE

-37.0%

Sector

Healthcare

Industria

Biotechnology

CEO

Harout Semerjian

Empleados

258

Fecha IPO

2018-01-29

País

US